Molecular therapy of pancreatic cancer

Minerva Endocrinologica

Volumn 35, Issue 1, 2010, Pages 27-33

  Plentz, R R ^a   Manns, M P ^a   Greten, T F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carcinoma, pancreatic ductal; Clinical trials as topic; Surgical procedures, operative

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEGACESTAT; BEVACIZUMAB; BRYOSTATIN 1; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETALOCIB; FOCAL ADHESION KINASE INHIBITOR; GEMCITABINE; GV 1001; MRK 003; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN S 100; S 100 P; SOMATOMEDIN C RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL STUDY; DRUG ERUPTION; DRUG SAFETY; HUMAN; MOLECULAR THERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMIDAZOLES; INDAZOLES; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PHTHALAZINES; PROGNOSIS; PYRIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953581007     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
2. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinic aspects. Gastroenterology 2005;128:1606-25.
3. Bardeesy N, DePinho RA. Pancreastic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
4. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G et al. S3-Guidelines "Exocrine Pancreatic Cancer 2007". Z Gastroenterol 2007;45:487-523.
5. Noble S, Goa KL. Gemcitabine: a review of its pharmacology and clinical potential in non-small lung cancer and pancreatic cancer. Drugs 1997;54:447-72. (Pubitemid 27395596)
6. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: curent therapy and continued progress. Gastroenterology. 2005;128:1642-54.
7. Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K et al. Biweekly high-dose gemdtabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Ann Oncol 2003;14:97-104. (Pubitemid 36150266)
8. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Cebtral European Cooperative Oncology Group. J Clin Oncol 2007;24:2212-7.
9. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-8.
10. Phillip PA. Targeted therapies for pancreatic cancer. Gastrintest Cancer Res 2008;2:15-9.
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compraed with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trail of the National Cancer Institute of Canada Clinicial Trials Group. J Clin Oncol 2007;25:1960-6.
12. Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C et al. Erlotinib 150mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie. Anticancer Drug 2009; Epup ahead of print.
13. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer. A multicenter phase II Trial. J Clin Oncol 2004;22:2610-6.
14. Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008;9:39-44.
15. Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 2009;7:1032-6.
16. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
17. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003.
18. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
19. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm 2001;16:359-370. (Pubitemid 33151113)
20. Siu LL, Awada A., Takimoto CH, Piccart M, Schwartz B, Giannaris T et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51.
21. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A et al. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009;220:214-21.
22. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8.
23. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res 2005;11:407-9.
24. Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G et al. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol 2009; [Epub ahead of print].
25. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y,Gill S, Van Laethem JL et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;13:2231-7.
26. Baron M. An overwiew of the Notch signaling pathway. Semin Cell Dec Biol 2003;14:113-9.
27. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
28. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;6:565-76.
29. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV et al. Inhibition of ?-Secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009;136:1741-9.
30. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
31. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;3:483-93.
32. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005;5:459-67.
33. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastastic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Can Res 2008;14:1455-63.
34. Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C et al. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J 2009;4:339-43.
35. Bernhardt SL, Gjertsen MK, Trachsel S, Möller M, Eriksen JA, Meo M et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006;95:1474-82.
36. Arumugan T, Ramachandran V, Logsdon CD. Effect of chromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J natl Cancer Inst 2006;95:1806-18.
37. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008;29:1096-107.
38. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 2009 [Epub ahead of print.
39. Lam AP, Sparano JA, Vinciguerra V, Ocean AJ, Christos P, Hochster H et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2009 [Epub ahead of print].
40. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N et al. Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. JCO 2009;27:5660-9.
41. Tabernero J, Macarulla T. Changing the paradgim in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. JCO 2009;27:5487-491.